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ABSTRACT 
Mucopolysaccharidosis type II (MPSII), or Hunter syndrome, arises from a 
deficiency in iduronate 2-sulfatase (IDS), and it is characterized by progressive 
somatic and neurological involvement. The MPSII mouse model reproduces the 
features of MPSII patients. Systemic administration of the AAV2/5CMV-hIDS 
vector in MPSII mouse pups results in the full correction of glycosaminoglycan 
(GAG) accumulation in visceral organs and in the rescue of the defects and 
GAG accumulation in the central nervous system (CNS). Remarkably, in treated 
MPSII animals, this CNS correction arises from the crossing of the blood-brain 
barrier by the IDS enzyme itself, not from the brain transduction. Thus, I show 
in this thesis that early treatment of MPSII mice with one systemic injection of 
AAV2/5CMV-hIDS results in prolonged and high levels of circulating IDS that 
can efficiently and simultaneously rescue both visceral and CNS defects for up 
to 18 months after therapy. 
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 INTRODUCTION 
1. BIOSYNTHESIS OF LYSOSOMAL ENZYMES 
Newly synthesized glycoproteins originating from the rough ER pass through 
the Golgi stacks and are then sorted to various destinations. Along this route, 
lysosomal enzymes are recognized by GlcNAc-P-T and phosphorylated in the 
intermediate compartment (cis-Golgi network; CGN) and then acted upon by 
“uncovering” enzyme (phosphodiester glycosidase) in the trans-Golgi network 
(TGN). Beyond the TGN, trafficking of lysosomal enzymes is primarily 
mediated by the MPRs through early endosomes to late endosomes, in which 
their lysosomal enzyme cargo is released. Smaller amounts of lysosomal 
enzymes can escape capture by MPRs and be secreted into the extracellular 
fluid. Lysosomal enzymes can also reenter the cell by binding to cell-surface 
MPRs and subsequent endocytosis (Figure 1) 1-3. Once in the endocytic 
pathway, internalized lysosomal enzymes can intermingle with those following 
the biosynthetic route, as depicted. Additional pathways for MPRs include 
recycling from the early endosome to the cell surface and back to the TGN, and 
from the recycling endosome and the late endosome, following release of their 
lysosomal enzyme cargo. 
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Figure 1. Biosynthesis and localization of lysosomal enzymes through the internal and 
external pathways of mannose-6-phosphate receptor 
Nascent lysosomal enzymes are glycosylated (green circles) in the endoplasmic reticulum 
(ER) of cells. The enzymes then acquire the mannose 6-phosphate modification (red circles) 
in the Golgi apparatus (Golgi) where they bind the mannose 6-phosphate receptor (M6PR). 
The majority (heavy arrows) of the enzymes are then trafficked to the mature lysosome 
(Lys). A minority (fine arrows) of the lysosomal enzymes are secreted from the cell. 
Extracellular phosphorylated or nonphosphorylated enzyme can bind the plasma membrane-
localized M6PR or the mannose receptor (ManR), respectively. Both receptors mediate the 
endocytosis and subsequent lysosomal targeting of the exogenous enzymes. 
 
 
2. LYSOSOMAL STORAGE DISEASES (LSD) 
Lysosomal storage diseases (LSDs) are a group of approximately 40 rare 
inherited metabolic disorder that result from defects in lysosomal function. 
Lysosomal storage diseases result when a specific organelle in the cells of body– 
the lysosome – malfunctions 4.  Lysosomal storage disorders are caused by 
lysosomal dysfunction usually as a consequence of deficiency of a single 
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enzyme required for the metabolism of lipids, glycoproteins (sugar containing 
proteins) or so-called mucopolysaccharides. Individually, LSDs occur with 
incidences of less than 1:100.000, however, as a group the incidence is about 
1:5000 - 1:10.000 5-8. Most of these disorders are autosomal recessively 
inherited 5, however a few are X-linked recessively inherited, such as Fabry 
diseases and Hunter syndrome (MPS II). The lysosome is commonly referred to 
as the cell’s recycling center because it processes unwanted material into 
substances that the cell can utilize. Lysosomes break down this unwanted matter 
via enzymes, highly specialized proteins essential for survival. Lysosomal 
disorders are triggered when a particular enzyme exists in too small an amount 
or is missing altogether. When this happens, substances accumulate in the cell. 
In other words, when the lysosome doesn’t function normally, excess products 
destined for breakdown and recycling are stored in the cell. Like other genetic 
diseases, individuals inherit lysosomal storage diseases from their parents. 
Although each disorder results from different gene mutations that translate into a 
deficiency in enzyme activity, they all share a common biochemical 
characteristic – all lysosomal disorders originate from an abnormal 
accumulation of substances inside the lysosome. Lysosomal storage diseases 
affect mostly children and they often die at a young and unpredictable age, many 
within a few months or years of birth. Many other children die of this disease 
following years of suffering from various symptoms of their particular disorder. 
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The symptoms of lysosomal storage disease vary, depending on the particular 
disorder and other variables like the age of onset, and can be mild to severe. 
They can include developmental delay, movement disorders, seizures, dementia 
deafness and/or blindness. Some people with lysosomal storage disease have 
enlarged livers (hepatomegaly) and enlarged spleens (splenomegaly), pulmonary 
and cardiac problems, and bones that grow abnormally. The lysosomal storage 
diseases are generally classified by the nature of the primary stored material 
involved, and can be broadly broken into the following:  
• Lipid storage disorders, mainly sphingolipidoses (including Gaucher’s 
and Niemann-Pick disease)  
o gangliosidosis (including Tay-Sachs disease) 
o leukodystrophies 
• mucopolysaccharidoses (including Hunter syndrome and Hurler disease) 
• glycoprotein storage disorders 
• mucolipidoses 
3. MUCOPOLYSACCHARIDOSES (MPSs) 
Mucopolysaccharidoses are a group of metabolic disorders caused by the 
absence or malfunctioning of lysosomal enzymes needed to break down 
molecules called glycosaminoglycans - long chains of sugar carbohydrates in 
each of our cells that help build bone, cartilage, tendons, corneas, skin and 
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connective tissue. Glycosaminoglycans (formerly called mucopolysaccharides) 
are also found in the fluid that lubricates our joints. Glycosaminoglycans 
(GAGs) or mucopolysaccharides are long unbranched polysaccharides 
consisting of a repeating disaccharide unit. The repeating unit consists of a 
hexose (six-carbon sugar) or a hexuronic acid, linked to a hexosamine (six-
carbon sugar containing nitrogen). Protein cores made in the rough endoplasmic 
reticulum are posttranslationally modified by glycosyltransferase in the Golgi 
apparatus, where GAG disaccharides are added to protein cores to yield 
proteoglycans. This family of carbohydrates is essential or important for life. 
GAGs form an important component of connective tissues. GAG chains may be 
covalently linked to a protein to form proteoglycans. Some examples of 
glycosaminoglycan uses in nature include heparin as an anticoagulant, 
hyaluronan as a component in the synovial fluid lubricant in body joints, and 
chondroitins which can be found in connective tissues, cartilage and tendons. 
People with a mucopolysaccharidosis either do not produce enough of one of the 
11 enzymes required to break down these sugar chains into simpler molecules, 
or they produce enzymes that do not work properly. Over time, these 
glycosaminoglycans collect in the cells, blood and connective tissues. The result 
is permanent, progressive cellular damage which affects appearance, physical 
abilities, organ and system functioning, and, in most cases, mental development. 
The mucopolysaccharidoses are part of the lysosomal storage disease family, 
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that result when a specific organelle in our body's cells – the lysosome – 
malfunctions. The lysosome is commonly referred to as the cell’s recycling 
center because it processes unwanted material into substances that the cell can 
utilize. Lysosomes break down this unwanted matter via enzymes, highly 
specialized proteins essential for survival. Lysosomal disorders like 
mucopolysaccharidosis are triggered when a particular enzyme exists in too 
small an amount or is missing altogether. The mucopolysaccharidoses share 
many clinical features but have varying degrees of severity. These features may 
not be apparent at birth but progress as storage of glycosaminoglycans affects 
bone, skeletal structure, connective tissues, and organs. Neurological 
complications may include damage to neurons as well as pain and impaired 
motor function. This results from compression of nerves or nerve roots in the 
spinal cord or in the peripheral nervous system, the part of the nervous system 
that connects the brain and spinal cord to sensory organs such as the eyes and to 
other organs, muscles, and tissues throughout the body. Depending on the 
mucopolysaccharidosis subtype, affected individuals may have normal intellect 
or may be profoundly retarded, may experience developmental delay, or may 
have severe behavioral problems. Many individuals have hearing loss, either 
conductive (in which pressure behind the ear drum causes fluid from the lining 
of the middle ear to build up and eventually congeal), neurosensitive (in which 
tiny hair cells in the inner ear are damaged), or both. Communicating 
                                                                                                                                       
 12 
hydrocephalus — in which the normal circulation of cerebrospinal fluid 
becomes blocked over time and causes increased pressure inside the head — is 
common in some of the mucopolysaccharidoses. Surgically inserting a shunt 
into the brain can drain fluid. The eye's cornea often becomes cloudy from 
intracellular storage, and glaucoma and degeneration of the retina also may 
affect the patient's vision. Physical symptoms generally include coarse or rough 
facial features (including a flat nasal bridge, thick lips, and enlarged mouth and 
tongue), short stature with disproportionately short trunk (dwarfism), dysplasia 
(abnormal bone size and/or shape) and other skeletal irregularities, thickened 
skin, enlarged organs such as liver (hepatomegaly) or spleen (splenomegaly), 
hernias, and excessive body hair growth. Short and often claw-like hands, 
progressive joint stiffness, and carpal tunnel syndrome can restrict hand mobility 
and function. Recurring respiratory infections are common, as are obstructive 
airway disease and obstructive sleep apnea. Many affected individuals also have 
heart disease, often involving enlarged or diseased heart valves. Seven distinct 
clinical types and numerous subtypes of the mucopolysaccharidoses have been 
identified. Although each mucopolysaccharidosis (MPS) differs clinically, most 
patients generally experience a period of normal development followed by a 
decline in physical and/or mental function. 
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4. SULFATASES AND MSD (MULTIPLE SULFATASE DEFICIT) 
Each Mucopolysaccharidosis is caused by an enzymatic deficit of a specific 
sulfatase. 
Sulfatases are hydrolases that cleave sulfate esters from a wide range of 
substrates, including glycosaminoglycans, sulfolipids, and steroid sulfates 9; 10. 
This protein family is represented in most eukaryotes and prokaryotes, with 
some notable exceptions such as Saccharomices cerevisiae. While in 
prokaryotes sulfatases are involved in sulfur scavenging, in vertebrates they are 
implicated in the turnover and degradation of sulfated compounds, mostly 
complex molecules that are hydrolyzed in lysosomes in concert with acidic 
glycosidases. Functional correlation among sulfatases is reflected in a high 
degree of amino acid sequence similarity along the entire length of the proteins, 
suggesting that they have evolved from a common ancestral gene 9; 11. The three-
dimensional structures of two human sulfatases (ARSA and ARSB) were 
determined, allowing the identification of the sulfatase active site, which 
contains a highly conserved cysteine residue as part of a metal binding site, 
closely resembling the active site of alkaline phosphatases 12; 13. Sulfatases 
undergo a common and unique posttranslational modification, which is essential 
for catalytic activity and occurs within the endoplasmic reticulum before the 
sorting of sulfatases to different cellular compartments. This newly discovered 
protein modification mechanism, which allows the conversion of the highly 
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conserved cysteine residue localized at the active site of sulfatases into Cα-
formylglycine, has been highly conserved during evolution from bacteria to man 
14; 15. Bacterial sulfatases may have either a cysteine or a serine at their active 
site, and both of these are modified to formylglycine, albeit by a different 
protein machinery 16; 17. 
To date, thirteen sulfatase genes have been identified in humans 10; 18; 19. They 
encode enzymes with different substrate specificity and subcellular localization 
such as lysosomes, Golgi, and ER 10. Four of these genes, ARSC, ARSD, ARSE, 
and ARSF, encoding arylsulfatase C, D, E, and F, respectively, are located 
within the same chromosomal region (Xp22.3). They share significant sequence 
similarity and a nearly identical genomic organization, indicating that they arose 
from duplication events that occurred recently during evolution 11; 20. 
The importance of sulfatases in human metabolism is underscored by the 
identification of at least eight human monogenic diseases caused by the 
deficiency of individual sulfatase activities 10. Most of these conditions are 
lysosomal storage disorders in which phenotypic consequences depend on the 
type and tissue distribution of the stored material. 
Among them are five different types of mucopolysaccharidoses (MPS types II, 
IIIA, IIID, IVA, and VI) due to deficiencies of sulfatases acting in the 
catabolism of glycosaminoglycans 4 and metachromatic leukodystrophy (MLD), 
which is characterized by the storage of sulfolipids in the central and peripheral 
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nervous systems leading to severe and progressive neurologic deterioration 21. In 
addition, two human diseases are caused by deficiencies of non lysosomal 
sulfatases. These include X-linked ichthyosis, a skin disorder due to steroid 
sulfatase (STS/ARSC) deficiency, and chondrodysplasia punctata, a disorder 
affecting bone and cartilage due to arylsulfatase E (ARSE) deficiency 20. ARSE 
is also implicated in a drug-induced human malformation syndrome, Warfarin 
embryopathy, caused by inhibition of the enzymatic activity due to in utero 
exposure to warfarin during pregnancy 20. 
In an intriguing human monogenic disorder, multiple sulfatase deficiency 
(MSD), all sulfatase activities are simultaneously defective 10; 22; 23. 
Consequently, the phenotype of this severe multisystemic disease combines the 
features observed in individual sulfatase deficiencies. The posttranslational 
modification which is required for the activity of all sulfatases was found to be 
defective in a cell line from a patient with MSD, suggesting that this disorder is 
caused by a mutation in a gene, or genes, implicated in the cysteine-to-
formylglycine conversion machinery 14. In spite of an intense biological and 
medical interest, efforts aimed at the identification of the MSD gene have been 
hampered by the rarity of MSD patients and consequent lack of suitable familial 
cases to perform genetic mapping. 
Recently, It has been identified the SUMF1 gene (SUlfatase Modifying Factor 
1). SUMF1 encode for a protein that is responsible of activation of all human 
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sulfatases. The deficit of this gene causes the MSD (Multiple Sulfatase Deficit) 
24; 25. 
5. MUCOPOLYSACCHARIDOSIS TYPE II (MPSII) 
Hunter syndrome, or mucopolysaccharidosis Type II, is a lysosomal storage 
disease caused by a deficient (or absent) enzyme, iduronate-2-sulfatase (I2S). 
The syndrome is named after physician Charles A. Hunter (1873-1955), who 
first described it in 1917. MPS II, is a serious genetic disorder that primarily 
affects males. It interferes with the body's ability to break down and recycle 
specific mucopolysaccharides, also known as glycosaminoglycans or GAG. In 
Hunter syndrome, GAG builds up in cells throughout the body due to a 
deficiency or absence of the enzyme iduronate-2-sulfatase (I2S). This buildup 
interferes with the way certain cells and organs in the body function and leads to 
a number of serious symptoms. As the buildup of GAG continues throughout the 
cells of the body, signs of Hunter syndrome become more visible. Physical 
manifestations for some people with Hunter syndrome include distinct facial 
features, a large head, and an enlarged abdomen. People with Hunter syndrome 
may also experience hearing loss, thickening of the heart valves leading to a 
decline in cardiac function, obstructive airway disease, sleep apnea, and 
enlargement of the liver and spleen. Range of motion and mobility may also be 
affected. In some cases of Hunter syndrome, central nervous system 
involvement leads to developmental delays and nervous system problems. Not 
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all people with Hunter syndrome are affected by the disease in exactly the same 
way, and the rate of symptom progression varies widely. However, Hunter 
syndrome is always severe, progressive, and life-limiting. 
The visible signs and symptoms of Hunter syndrome (MPS II) in younger 
people are usually the first clues leading to a diagnosis. In general, the time of 
diagnosis usually occurs from about 2 to 4 years of age. The most commonly 
used laboratory screening test for an MPS disorder is a urine test for GAG. It is 
important to note that the urine test for GAG can occasionally be normal and yet 
the child still may have an MPS disorder. A definitive diagnosis of Hunter 
syndrome is made by measuring I2S activity in serum, white blood cells, or 
fibroblasts from skin biopsy. In some people with Hunter syndrome, analysis of 
the I2S gene can determine clinical severity. Prenatal diagnosis is routinely 
available by measuring I2S enzymatic activity in amniotic fluid or in chorionic 
villus tissue. Since Hunter syndrome is an inherited disorder (X-linked 
recessive) that primarily affects males, it is passed down from one generation to 
the next in a specific way. The incidence of Hunter syndrome is estimated to be 
about 1 in 165,000 male births. The I2S gene is located on the X chromosome. If 
a male has an abnormal copy of the I2S gene, he will develop Hunter syndrome. 
A male can obtain an abnormal copy of the I2S gene in one of two ways. His 
mother is often a carrier; i.e., she has one abnormal and one normal I2S gene, 
and she passes along the abnormal gene to him. However, during egg and sperm 
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formation, a mutation can develop in the I2S gene on his X chromosome. In this 
second case, the mother is not a carrier and the risk of a spontaneous mutation 
occurring again in a future sibling is low but not zero. Females can carry one 
abnormal copy of the I2S gene and are usually not affected. In the MPSII 
patients It has been identified different kind of mutations (point mutation, 
deletion and insertion) 26, which causes the lack of IDS enzymatic activity. The 
IDS enzyme takes part in the first catabolic step of dermatan and heparan sulfate 
4; 27 (Figure 2).  
The human body depends on a vast array of biochemical reactions to support 
critical functions, including the production of energy, growth and development, 
communication within the body, and protection from infection. Another critical 
function is the breakdown of large biomolecules, which is the underlying 
problem in Hunter syndrome (MPS II) and related storage disorders. The 
biochemistry of Hunter syndrome is related to a problem in a part of the 
connective tissue of the body known as the extracellular matrix. This matrix is 
made up of a variety of sugars and proteins and helps to form the architectural 
framework of the body. The matrix surrounds the cells of the body in an 
organized meshwork and functions as the glue that holds the cells of the body  
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Figure 2(A-B): Catabolic process of dermatan (A: left of figure) and heparan sulfate 
(right of figure). 
 
together. One of the parts of the extracellular matrix is a complex molecule 
called a proteoglycan. Like many components of the body, proteoglycans need 
to be broken down and replaced. When the body breaks down proteoglycans, 
one of the resulting products is mucopolysaccharides, otherwise known as GAG. 
There are several types of GAG, each found in certain characteristic places in 
the body. In Hunter syndrome, the problem concerns the breakdown of two 
GAG: dermatan sulfate and heparan sulfate. In people with Hunter syndrome, 
the IDS enzyme is either partially or completely inactive. As a result, GAG 
build up in cells throughout the body, particularly in tissues that contain large 
amounts of dermatan sulfate and heparan sulfate. As this buildup continues, it 
interferes with the way certain cells and organs in the body function and leads to 
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a number of serious symptoms. The rate of GAG buildup is not the same for all 
people with Hunter syndrome, resulting in a wide spectrum of medical 
problems. 
• Children with MPS II A 28; 29 (Figure 3) are affected by coarse facial 
features, skeletal irregularities, obstructive airway and respiratory 
complications, short stature, joint stiffness, retinal degeneration (but no 
corneal clouding), communicating hydrocephalus 30, chronic diarrhea, 
enlarged liver and spleen, and progressive hearing loss. Whitish skin 
lesions may be found on the upper arms, back, and upper legs. Death from 
upper airway disease or cardiovascular failure usually occurs by age 15.  
The symptoms of Hunter syndrome (MPS II) are generally not apparent at birth, 
but usually start to become noticeable after the first year of life. Often, the first 
symptoms of Hunter syndrome may include abdominal hernias, ear infections, 
runny noses, and colds. Since these symptoms are quite common among all 
infants, they are not likely to lead to make a diagnosis of Hunter syndrome right 
away. As the buildup of GAG continues throughout the cells of the body, signs 
of Hunter syndrome become more visible. Physical appearances of many 
children with Hunter syndrome include a distinctive coarseness in their facial 
features, including a prominent forehead, a nose with a flattened bridge, and an 
enlarged tongue. For this reason, unrelated children with Hunter syndrome often 
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look alike. They may also have a large head as well as an enlarged abdomen. 
Many continue to have frequent infections of the ears and respiratory tract. The 
continued storage of GAG in cells can lead to organs being affected in important 
ways. The thickening of the heart valves along with the walls of the heart can 
result in progressive decline in cardiac function. The walls of the airway may 
become thickened as well, leading to breathing problems while sleeping 
(obstructive airway disease). People with Hunter syndrome may also have 
limited lung capacity due to pulmonary involvement. As the liver and spleen 
grow larger with time, the belly may become distended, making hernias more 
noticeable. All major joints (including the wrists, elbows, shoulders, hips, and 
knees) may be affected by Hunter syndrome, leading to joint stiffness and 
limited motion. Progressive involvement of the finger and thumb joints results in 
decreased ability to pick up small objects. The effects on other joints, such as 
hips and knees, can make it increasingly difficult to walk normally. If carpal 
tunnel syndrome develops, a further decrease in hand function can occur. The 
bones themselves may be affected, resulting in short stature. In addition, pebbly, 
ivory-colored skin lesions may be found on the upper arms and legs and upper 
back of some people with Hunter syndrome. The presence or absence of the skin 
lesions is not helpful, however, in predicting clinical severity in Hunter 
syndrome. Finally, the storage of GAG in the brain can lead to delayed 
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development with subsequent mental retardation. The rate and degree of 
progression may be different for each person with Hunter syndrome. 
• Physical characteristics of MPS II B 28; 29 (Figure 3) are less obvious and 
progress at a much slower rate. Diagnosis is often made in the second 
decade of life. Intellect and social development are not affected 29. 
Skeletal problems may be less severe, but carpal tunnel syndrome and 
joint stiffness can restrict movement and height is somewhat less than 
normal. Other clinical symptoms include hearing loss, poor peripheral 
vision, diarrhea, and sleep apnea, although respiratory and cardiac 
complications can contribute to premature death. Persons with MPS II B 
may live into their 50s or beyond. 
It is important to note that though the term mild is used by physicians in 
comparing people with Hunter syndrome, the effects of even mild disease are 
quite serious. Two of the most significant areas of variability concern the degree 
of mental retardation and expected lifespan. Some people who have Hunter 
syndrome are not mentally retarded and live into their 20s or 30s; there are 
occasional reports of people who have lived into their 50s or 60s. The quality of 
life remains high in a large number of people, and many adults are actively 
employed. In contrast, others with Hunter syndrome develop severe mental 
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impairment and have life expectation of 15 years or less. There are estimated to 
be approximately 2,000 people afflicted with Hunter Syndrome worldwide. 
 
 
 
 
 
 
Figure 3(A-B): Patients affected by MPSIIA (A: left of figure) and by MPSIIB (B: right of 
figure). 
 
6. MPSII KNOCK-OUT MOUSE MODEL  
The MPSII mouse model (Idsy/-) was generated by targeting exon 4 and part of 
exon 5 of the gene, and it has been characterized 31; 32. 
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7. THE GENE THERAPY 
Gene therapy is the insertion of genes into an individual's cells and tissues to 
treat a disease, such as a hereditary disease in which a deleterious mutant allele 
is replaced with a functional one.  
Germ line gene therapy 
In the case of germ line gene therapy, germ cells, i.e., sperm or eggs, are 
modified by the introduction of functional genes, which are ordinarily integrated 
into their genomes. Therefore, the change due to therapy would be heritable and 
would be passed on to later generations. This new approach, theoretically, 
should be highly effective in counteracting genetic disorders and hereditary 
diseases. However, many jurisdictions prohibit this for application in human 
beings, at least for the present, for a variety of technical and ethical reasons. 
Somatic gene therapy 
In the case of somatic gene therapy, the therapeutic genes are transferred into the 
somatic cells of a patient. Any modifications and effects will be restricted to the 
individual patient only, and will not be inherited by the patient's offspring or 
later generations.  
There are a variety of different methods to replace or repair the genes targeted in 
gene therapy. One of these is the replacement of gene using the viral vectors. 
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8. THE VIRAL VECTORS AND THE ADENO-ASSOCIATED VIRUSES 
(AAV) 
All viruses bind to their hosts and introduce their genetic material into the host 
cell as part of their replication cycle. This genetic material contains basic 
instructions of how to produce more copies of these viruses, hijacking the body's 
normal production machinery to serve the needs of the virus. The host cell will 
carry out these instructions and produce additional copies of the virus, leading to 
more and more cells becoming infected. Some types of viruses physically insert 
their genes into the host's genome (a defining feature of retroviruses, the family 
of viruses that includes HIV, is that the virus will introduce the enzyme reverse 
transcriptase into the host and thus use its RNA as the instructions). This 
incorporates the genes of that virus among the genes of the host cell for the life 
span of that cell. The mechanism by which gene transfer occurs is the 
transduction 33. Different kind of viral vectors can be used in the gene therapy 
protocols. 
Retroviruses 
The genetic material in retroviruses is in the form of RNA molecules, while the 
genetic material of their hosts is in the form of DNA. When a retrovirus infects a 
host cell, it will introduce its RNA together with some enzymes, namely reverse 
transcriptase and integrase, into the cell. This RNA molecule from the retrovirus 
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must produce a DNA copy from its RNA molecule before it can be integrated 
into the genetic material of the host cell. The process of producing a DNA copy 
from an RNA molecule is termed reverse transcription. It is carried out by one 
of the enzymes carried in the virus, called reverse transcriptase. After this DNA 
copy is produced and is free in the nucleus of the host cell, it must be 
incorporated into the genome of the host cell. That is, it must be inserted into the 
large DNA molecules in the cell (the chromosomes). This process is done by 
another enzyme carried in the virus called integrase. Now that the genetic 
material of the virus has been inserted, it can be said that the host cell has been 
modified to contain new genes. If this host cell divides later, its descendants will 
all contain the new genes. Sometimes the genes of the retrovirus do not express 
their information immediately. One of the problems of gene therapy using 
retroviruses is that the integrase enzyme can insert the genetic material of the 
virus into any arbitrary position in the genome of the host; it randomly shoves 
the genetic material into a chromosome. If genetic material happens to be 
inserted in the middle of one of the original genes of the host cell, this gene will 
be disrupted (insertional mutagenesis). If the gene happens to be one regulating 
cell division, uncontrolled cell division (i.e., cancer) can occur. This problem 
has recently begun to be addressed by utilizing zinc finger nucleases or by 
including certain sequences such as the beta-globin locus control region to direct 
the site of integration to specific chromosomal sites. Gene therapy trials using 
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retroviral vectors to treat X-linked severe combined immunodeficiency (X-
SCID) represent the most successful application of gene therapy to date. More 
than twenty patients have been treated in France and Britain, with a high rate of 
immune system reconstitution observed. Similar trials were halted or restricted 
in the USA when leukemia was reported in patients treated in the French X-
SCID gene therapy trial. To date, four children in the French trial and one in the 
British trial have developed leukemia as a result of insertional mutagenesis by 
the retroviral vector. All but one of these children responded well to 
conventional anti-leukemia treatment. Gene therapy trials to treat SCID due to 
deficiency of the Adenosine Deaminase (ADA) enzyme continue with relative 
success in the USA, Britain, Italy and Japan. 
Adenoviruses 
Adenoviruses are viruses that carry their genetic material in the form of double-
stranded DNA. They cause respiratory, intestinal, and eye infections in humans 
(especially the common cold). When these viruses infect a host cell, they 
introduce their DNA molecule into the host. The genetic material of the 
adenoviruses is not incorporated (transient) into the host cell's genetic material. 
The DNA molecule is left free in the nucleus of the host cell, and the 
instructions in this extra DNA molecule are transcribed just like any other gene. 
The only difference is that these extra genes are not replicated when the cell is 
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about to undergo cell division so the descendants of that cell will not have the 
extra gene. As a result, treatment with the adenovirus will require 
readministration in a growing cell population although the absence of integration 
into the host cell's genome should prevent the type of cancer seen in the SCID 
trials. This vector system has been promoted for treating cancer and indeed the 
first gene therapy product to be licensed to treat cancer, Gendicine, is an 
adenovirus. Gendicine, an adenoviral p53-based gene therapy was approved by 
the Chinese FDA in 2003 for treatment of head and neck cancer. Concerns about 
the safety of adenovirus vectors were raised after the 1999 death of Jesse 
Gelsinger while participating in a gene therapy trial. Since then, work using 
adenovirus vectors has focused on genetically crippled versions of the virus. 
Adeno-associated viruses 
Adeno-associated viruses, from the parvovirus family 34, are small viruses with a 
genome of single stranded DNA. The major part of population is seropositive to 
the AAV 35; 36. The wild type AAV can insert genetic material at a specific site 
on chromosome 19 with near 100% certainty 37; 38. But the recombinant AAV, 
which does not contain any viral genes and only the therapeutic gene, does not 
integrate into the genome. Instead the recombinant viral genome fuses at its ends 
via the ITR (inverted terminal repeats) recombination to form circular, episomal 
forms which are predicted to be the primary cause of the long term gene 
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expression. There are a few disadvantages to using AAV, including the small 
amount of DNA it can carry (low capacity) and the difficulty in producing it. 
This type of virus is being used, however, because it is non-phatogenic (most 
people carry this harmless virus). In contrast to adenoviruses, most people 
treated with AAV will not build an immune response to remove the virus and 
the cells that have been successfully treated with it. Several trials with AAV are 
on-going or in preparation, mainly trying to treat muscle and eye diseases. 
However, clinical trials have also been initiated where AAV vectors are used to 
deliver genes to the brain. This is possible because AAV viruses can infect non-
dividing (quiescent) cells 39, such as neurons in which their genomes are 
expressed for a long time.  
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MATERIALS AND METHODS 
1. Animals 
The female heterozygous MPSII mice were described 32.  
 
2. Blood and tissue collection    
Blood (50 µl) was collected in EDTA at different time points after the injection: 
T1, T6, T12, and T18 (until T12 for the Idsy/- control mice). The blood was 
centrifuged at 10,000x g for 10 min at 4 ˚C, and the serum (supernatant) was 
used for the enzyme assays. Tissues were collected 1 month and 18 months (14 
months for the Idsy/- control mice) after injection. The mice were anaesthetized 
and sacrificed by cardiac perfusion: the left ventricle was cannulated, an incision 
was made in the right atrium, and the animals were perfused with PBS. The 
organs were collected. Half of each organ was fixed (for Alcian-blue and H&E 
staining, and IHC), and the other half was frozen in dry ice before being 
processed for the IDS activity assay and  total RNA extraction. 
 
3. AAV vector construction and production    
The human IDS coding sequence was cloned into the pAAV2.1-CMV-LacZ 
plasmid40 by replacing the LacZ sequence. The resulting pAAV2.1-CMV-hIDS 
and pAAV2.1-LacZ were then triple transfected in sub-confluent 293 cells, 
along with the pAd-Helper and the pack2/5 packaging plasmids, as described 41. 
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The recombinant AAV2/5 vectors were purified by two rounds of CsCl, as 
described 41. Vector titers, expressed as genome copies (GC/ml), were assessed 
by real-time PCR (GeneAmp 7000 Applied Biosystem), as described 42. The 
AAV vectors were produced by the TIGEM AAV Vector Core Facility. 
 
4. IDS activity assay    
The tissues for analysis were homogenized in water. Serum and tissue protein 
concentrations were determined using the Bio-Rad colorimetric assay (Bio-Rad, 
Hercules, CA, USA). The IDS assay was performed as described 43: briefly, 50 
µg total protein extract was incubated with 20 µl of the fluorogenic substrate, 4-
methylumbelliferyl-α-iduronide-2-sulfate (Muscerdam Substrates), for 4 h at 37 
˚C. Then, 10 µl of purified α -iduronidase from rabbit liver (Muscerdam 
Substrates) and 40 µl of McIlvain’s buffer (0.4 M Na-phosphate/ 0.2 M Na-
citrate, pH 4.5) were added to the reaction mixture, which was then incubated 
for an additional 24 h at 37 ˚C. The reaction was stopped by adding carbonate 
stop buffer (0.5 M NaHCO3/0.5 M Na2CO3, pH 10.7), and the fluorescence of 
the 4-methylumbelliferone liberated was measured using 365 nm excitation and 
460 nm emission in a fluorimeter (BIO-RAD VersaFluor Fluorometer). The 
enzyme activities were expressed as nmol/4 h/mg protein, as calculated through 
the standard curve of the fluorogenic substrate, 4-methylumbelliferyl-α-
iduronide (Sigma-Aldrich). 
                                                                                                                                       
 32 
5. Alcian blue and H&E staining 
After the perfusion of the animals with PBS, the tissues were collected and fixed 
in methacarn solution (30% chloroform, 60% methanol and 10% acetic acid) for 
24 h at 4 ˚C. The next day, the tissues were embedded in paraffin (Sigma-
Aldrich) after their dehydration with a 70% to 100% ethanol gradient. Finally, 
the tissues were sectioned into 7-µm-thick serial sections. The tissue sections 
were stained with 1% Alcian blue (Sigma-Aldrich) in hydrochloric acid. The 
counterstaining was performed for 2 min with Nuclear-Fast red (Sigma-
Aldrich). For the H&E staining, the brains were collected after PBS perfusion 
and fixed in methacarn solution, embedded in paraffin, sectioned into 7-µm-
thick sections, and then stained with Hematoxylin (Sigma-Aldrich) for 2 min. 
The counterstaining was performed with Eosin (Sigma-Aldrich) for 30 s. 
 
6. Immunohistochemistry 
Mice brains were collected after PBS perfusion and fixed with 10% neutral 
buffered formalin (NBF), pH 7.0, for 12 h at 4 ˚C. Then the brains were 
embedded in paraffin (Sigma-Aldrich), and then dehydrated with a 70% to 
100% ethanol gradient. Immunohistochemistry analyses were performed on 7-
µm-thick serial sections. The specimens were incubated for 1 h with blocking 
solution (Tris-buffered saline, 0.2% Tween-20 [Sigma-Aldrich], and 10% 
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normal horse serum, Vectastain Elite ABC kit) before incubation overnight with 
the primary antibodies.  
For immunohistochemical analysis of NeuN, ubiquitin, GFAP and α -synuclein 
of the paraffin-embedded, formalin-fixed brains, the avidin-biotin complex 
(ABC) method was used (Vectastain Elite ABC kit). Monoclonal rabbit 
antibodies against murine NeuN (diluted 1:100; Chemicon International), 
ubiquitin (polyclonal; diluted 1:50; Abcam, Cambridge, UK), GFAP (diluted 
1:200; Sigma-Aldrich) and α-synuclein (diluted 1:250; Abcam, Cambridge, UK) 
antibodies were used. For detection of CD68, a monoclonal rat antibody against 
murine CD68 was used (diluted 1:250; AbD Serotec). Then a secondary 
biotinylated horse anti-rabbit IgG and streptavidin-biotin-peroxidase complex 
(Vectastain Elite ABC kit) were used for 1 h of incubation (for anti-NeuN, 
ubiquitin, GFAP, α-synuclein). For anti-CD68 secondary biotinylated horse anti-
rat IgG was used (Vector Laboratories, CA, USA). The colour was developed 
using the ABC Elite Vector Staining kit and the horseradish peroxidase substrate 
(Vector Laboratories, Inc., Burlingame, CA). For the detection of apoptotic cells 
in the brain sections, we used the TUNEL staining kit (Chemicon International), 
according to the manufacturer instructions. 
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7. RT-PCR 
RNA was extracted from the brains, livers and lungs of wt, Idsy/- and injected 
Idsy/- mice sacrificed 1 month and 18 months after treatment. The cDNAs were 
obtained by Superscript III Reverse Transcriptase kits (Invitrogen). The primers 
used were: forward primer hIDS: 5’-cagcagcgagaagtacgaga-3’; reverse primer 
hIDS: 5’-ttctggaactccttggggta-3’; forward primer mIDS: 5’-tccaccttatcatccatcct-
3’; reverse primer mIDS: 5’-gccagggttatgttttccaa-3’; forward primer LacZ: 5’-
actatcccgaccgccttact-3’; reverse primer LacZ: 5’- tagcggctgatgttgaactg-3’; 
forward primer mGAPDH: 5’-gtcggtgtgaacggatttg-3’; and reverse primer 
mGAPDH: 5’-caatgaaggggtcgttgatg-3’. The amplicon sizes were, respectively, 
241, 285, 173 and 100 bp. Each reaction was carried out using 300 ng of sample 
cDNA in a final volume of 25 µl (with EuroTaq-Euroclone). The following 
cycling parameters were used: 5 min at 94 °C, followed by 33 cycles of 
denaturation at 94 °C for 1 min, annealing at 59 °C for 1 min (for hIDS and 
LacZ), or at 56 °C for 1 min (for mIDS and mGAPDH), extension at 72 °C for 1 
min,  followed by 7 min at 72 °C. 
 
8. Quantitative real-time PCR 
Real-time PCR was performed on genomic DNA extracted from the brain and 
liver of the injected mice 1 month after treatment (on a LightCycler 480 Probes 
Master Roche machinery). The primers used were: forward primer BGH: 5’-
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tctagttgccagccatctgttgt-3’; reverse primer BGH: 5’-tgggagtggcaccttcca-3’ and 
the TaqMan probe 5’-6FAM-tcccccgtgccttccttgacc-TAMRA-3’. Amplicon size 
was 65 bp. Each reaction was carried out using 100 ng of sample genomic DNA 
in a final volume of 25 µl (with LightCycler 480 Probes Master kit, Roche). As 
standard, the diluted gene transfer vector was used (from 1×107 copies to 1 
copy/reaction). The following cycling parameters were used: 5 min at 95 °C, 
followed by 45 cycles of denaturation at 95 °C for 10 sec, annealing at 60 °C for 
35 sec, extension at 72 °C for 1 sec, followed by 10 sec at 40 °C. 
All the reactions were performed in triplicate sets and the results were reported 
as the average of three reactions. 
To obtain the vector copy number for each cell, the values were divided by the 
number of cells corresponding to 100 ng of genomic mouse DNA. 
 
9. Quantitative analysis of GAG accumulation in the urine   
Urine from individual mice was collected in metabolic cages at different times 
during the treatment: T1, T6, T12 and T18 (until T12 for the Idsy/- control mice). 
The GAG levels in the urine were determined using the dimethylmethylene 
blue-based spectrophotometry of GAGs 44. These were normalized to the 
creatinine content. Urine creatinine was measured using a Creatinine Assay kit 
(Quidel Corporation, San Diego, CA, USA). Absorbance was read at 490 nm. 
The urinary GAG was expressed as mg GAG/mg creatinine. 
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10. Open-field test    
Treated Idsy/-+IDS (T18) and control mice (wt, Idsy/-) were tested during the 
same sessions to minimize any variability. The motor and the exploratory 
behaviours were assessed in an acrylic open arena, as described  45. 
 
11. Statistical analyses 
It was measured the statistical significance of compared measurements with the 
Student’s two-tailed t-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                       
 37 
RESULTS 
1. Knock-out mouse model of Hunter syndrome 
MPSII is an X-linked recessive lysosomal storage disorder that is caused by the 
lack of IDS activity. Iduronate-2-sulfatase (IDS) is the enzyme that removes the 
sulfate group from dermatan and heparan sulfate, and its inactivity results in 
MPSII, or Hunter syndrome, a rare X-linked inborn error of metabolism. 
Usually, only males are affected. The incidence of MPSII has been estimated at 
around 1 in 162,000 live births. The deficiency of IDS has been shown to be due 
to point mutations or deletions in the 24 kb IDS gene 26. As with all of the 
human sulfatases, IDS needs to be activated by sulfatase modifying factor 1 
(SUMF1) 24; 25. 
MPSII occurs in both severe and mild forms that cover a broad spectrum of 
symptoms with slow to rapid pathological progression. The severe form is 
characterized by progressive somatic and neurological involvement, with an 
onset between the second and fourth years of age and an early mortality. Facial 
features, hepatosplenomegaly, short stature, skeletal deformities, joint stiffness, 
severe retinal degeneration, and hearing impairment are coupled to an 
incremental deterioration of the neurological system 27. We and others always 
described the phenotype of the knock-out mouse model (Idsy/-) of MPSII 31; 32. 
The MPSII (Idsy/-) mouse model displays the features of Hunter syndrome 31. We 
observed that the onset of the gross morphological phenotype was clearly 
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manifested at 3–4 months of age, and it became progressively severe through 
their adult life; the affected mice usually died by 60–70 weeks of age. This 
phenotype includes craniofacial abnormalities, with a short cranium and 
alopecia; thickening of the digits was also seen. Furthermore, the older MPSII 
mice weighed less than each matched wild-type animal. The protein extracts 
prepared from tissue homogenates of the MPSII mice were tested for IDS 
activity using the fluorescent substrate 4-methylumbelliferyl-a-iduronate 2-
sulfate 31. IDS activity was undetectable in liver, spleen, lung, heart, kidney, 
skeletal muscle, brain and eye when compared with the activities of this enzyme 
in the wild-type tissues 32. 
IDS initiates the catabolism of the dermatan and heparan sulfate GAGs. The loss 
of IDS activity causes GAG accumulation within the urine and all tissues, with a 
progressive cellular vacuolization and the consequent cell death. We thus 
analyzed GAG accumulation in the early stages of the affected mice: at 1 day of 
age (p1) and at 3 days of age (p3). GAG accumulation was already detectable in 
the tissues at these early stages of life 32. GAG accumulation dramatically 
increased during the adult stages, and Alcian-blue staining of the paraffin-
embedded sections of liver, spleen, lung, heart, kidney and skeletal muscle of 
Idsy/- mice at 3 and 9 months of age showed high levels of GAG storage within 
the cells 32. This progressive increase in GAG lysosomal storage also caused 
skeleton deformation. In particular, a craniofacial abnormality was evident, 
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which was characterized by a longer length between the base of the ears and a 
shorter distance across the maxilla and the zygoma 32. The skeleton 
malformations also affected the performance in locomotor tests. Indeed, the 
MPSII mice showed irregular gait, abnormal walking pattern and poor 
locomotor and exploratory abilities in the open-field test 32. 
In addition, we observed that MPSII mice presented neuropathological defects 
32. 
 
2. IDS gene delivery in the MPSII mice 
MPSII is characterized by the involvement of many visceral organs, including 
the heart, kidney, liver, lung, muscle, spleen and brain. Previously, we used an 
AAV type 2/8 vector carrying human IDS cDNA under the control of the 
thyroxine-binding globulin liver-specific promoter (AAV2/8TBG-hIDS), to 
engineer liver secretion of IDS. 
We shown that systemic administration of AAV2/8TBG-hIDS can lead to very 
high levels of circulating IDS, which efficiently corrected the visceral organs 
through IDS uptake from the blood 32 and partially cleared glycosaminoglycan 
(GAG) accumulation in the choroid plexus of Idsy/- mice 32. We used the human 
IDS gene transfer to engineer the liver to secrete the active sulfatase into the 
blood stream at sufficiently high levels to systemic cross-correct the enzymatic 
deficiencies in the various tissues. We constructed an AAV type 2/8 vector 
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carrying the human IDS cDNA under the transcriptional control of the liver-
specific promoter of the TBG gene (AAV2/8TBG-IDS) 40; adult MPSII mice 
received 1.0 x 1011 particles of AAV2/8TBG-IDS in a volume of 200 ml via the 
tail vein 32.  
It was imperative to develop an efficient therapy to treat the CNS symptoms. 
Ideally, having circulating IDS that crosses the blood-brain barrier (BBB) would 
be highly preferred and would provide treatment of both visceral and CNS 
defects, simultaneously. 
The BBB is formed by a layer of endothelial cells of the brain microvasculature 
that regulates the passage of molecules between the blood and the CNS. Tight 
junctions block the passage of most molecules, except some specific substances 
that cross the BBB via receptor-mediated transport  46 (Figure 4).  
Enzyme-replacement therapy at high doses in mouse models of α-mannosidosis, 
MPSVII, and metachromatic leukodystrophy leads to enzyme delivery across 
the BBB, thereby partially reversing storage in brain tissues 47-49. Similarly, the 
intrahepatic administration of AAV2 vectors in MPSVII mice results in some 
correction of the CNS phenotype 50. 
To anticipate disease manifestation and to simultaneously treat the visceral and 
CNS defects of MPSII, we have been systemically administered the AAV type 
2/5 vector carrying human IDS cDNA, but here under the control of the 
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cytomegalovirus promoter (AAV2/5CMV-hIDS), in day 2 (p2) Idsy/- mouse 
pups. 
 
Figure 4. General structure of Blood-Brain Barrier (BBB). 
 
We used this type of vector because it has been shown to provide efficient 
transduction of several tissues, such as skeletal muscle and lung 51; 52.  
We injected groups of p2 Idsy/- pups in the temporal vein with 1 x 1011 
AAV2/5CMV-hIDS viral particles; along with a group of non-injected MPSII (n 
= 5) and of wild-type (n = 5) mice, these mice were all then analyzed in the 
following ways: 
 IV ventricle wt 2.5X 
III ventricle wt 2.5X 
Hippocampus 
Cerebellum 
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 (1) The mice under the therapeutic protocol were checked every 6 months for 
18 months for IDS activity in their plasma and for the GAG content of their 
urine.  
(2) The mice were sacrificed at two times after transduction: one group of 
injected mice (T1; n = 8) after 1 month and the other group of injected mice 
(T18; n = 4) at 18 month of therapy. In parallel, groups of untreated Idsy/- and 
wild-type control mice of the same age were sacrificed as controls. We analyzed 
all tissues of the sacrificed mice for IDS activity and GAG clearance. 
We observed full correction of the CNS symptoms and visceral defects. 
Furthermore, we provided evidence that correction of CNS storage and neuronal 
markers is due to the crossing of the BBB by IDS. 
 
3. Rescue of the IDS activity in the tissues and in the brain of adult MPSII 
mice by AAV2/5CMV-hIDS 
The data collected on the MPSII mice tissues and plasma at T1, T6, T12 and 
T18 are reported. The plasma IDS activity that we monitored every 6 months for 
18 months was extremely high, showing levels up to 5-fold higher in the treated 
mice in comparison to the WT mice and up to 60-fold higher in the treated mice 
in comparison to the Idsy/- control mice (Table 1). The untreated Idsy/- mice died 
at 14 months. In contrast, the life span of the treated animals was prolonged up 
to and beyond 18 months. 
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On average, the levels were always much higher than the wild-type activity 
throughout the period of the treatment, although there was a decrease in plasma 
IDS activity during the therapy. This fall of IDS activity might be due to a loss 
over time of viral DNA copies or to a slight immune response toward the 
transgene or toward the AAV capsid. The IDS plasma activity in untreated mice 
(Table 1) was not detectable.  
We sacrificed eight treated MPSII mice at T1 and four at T18 after gene 
delivery. As the control, two groups of five untreated and wild-type mice of 
comparable ages were sacrificed.  
We determined the IDS activities in protein extracts prepared from the 
homogenized tissues of all the control and treated mice. In the treated mice, 
there was a remarkable rescue of IDS activity that reached levels comparable to 
or higher than the IDS activities measured in the WT tissues; this was seen for 
all of the evaluated tissues from the treated mice that were sacrificed at T1 and 
T18. As expected, in the tissues of the untreated MPSII, the IDS activity was not 
detectable (Figure 5A). 
Surprisingly, a moderate rescue of IDS activity was evident in brain 
homogenates of T1 and T18 mice (Figure 5B).  
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Table 1. IDS activity in the plasma measured at different times after therapy (T1, T6, T12, 
and T18: 1, 6, 12, and 18 months after the injection, respectively) of WT (n = 3), Idsy/- (n = 3), 
and AAV2/5CMV-hIDS-injected Idsy/- mice. 
 
Altogether, these results demonstrate that the systemic injection of the 
AAV2/5CMV-hIDS viral particles results in an extremely efficient production, 
secretion and uptake of the IDS enzyme. 
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Moreover these results led to predict that IDS enzyme had crossed the BBB. 
Indeed, much higher IDS activity would be expected if there had been 
transduction of AAV2/5CMV-hIDS in the brain. 
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Figure 5. Increase in IDS Activity and Rescue of GAG Accumulation in Idsy/- Mice after 
Temporal Vein AAV2/5CMV-hIDS Injection 
(A) P2 Idsy/- mice sacrificed 1 (T1) and 18 (T18) months after therapy. IDS activities in the 
treated mice were measured in protein extracts of: WT (n = 5), Idsy/- (n = 5), T1 Idsy/-+IDS (n 
= 8), and T18 Idsy/-+IDS (n = 4) mice. (B) IDS measured in brain homogenates of the same 
groups of control and treated mice. Error bars indicate standard deviations. p < 0.05 
(Student’s t test).  
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4. Clearance of the lysosomal GAG accumulation in the tissues and in the 
urine of treated MPSII mice 
To determine whether the IDS activity mediated by AAV2/5CMV-hIDS was 
able to clear the GAG lysosomal storage of the MPSII mice, we measured the 
GAG content in the tissues and in the urine of control and treated mice. 
The urine of the treated MPSII (T1, n = 8; T18, n = 4), untreated (n = 3) and 
wild-type (n = 3) mice were analyzed for their GAG levels every 6 months for 
up to 18 months after the injections at T1, T6, T12, and T18.  
The GAG levels were normalized with respect to the urine creatinine content 
(GAG excretion is expressed as a ratio of milligrams of GAGs to milligrams of 
creatinine excretion). The GAG accumulation in the urine of the MPSII mice 
was approximately double the concentration found in the wild-type animals. 
GAGs were cleared in the urine of all of the treated mice for up to 18 months 
after the therapy, and their accumulation was almost fully normalized, as 
compared to WT levels (Table 2).  
For the tissues, we evaluated the GAG lysosomal storage using quantitative 
Alcian-blue staining. At T1 and T18, the organs of the sacrificed treated MPSII 
mice (T1, n = 8; T18, n = 4) were embedded in paraffin and the GAG 
accumulation analyzed in sections. 
As expected, the GAG lysosomal storage in the control, untreated MPSII tissues 
was highly positive in the Alcian-blue staining. 
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Table 2. GAG accumulation in the urine measured at different times after therapy (T1-T6-
T12-T18) (1-6-12-18 months after the injection, respectively) of wt (n = 3), Idsy/- (n = 3) and 
Idsy/- AAV2/5CMV-hIDS-injected mice. P<0.05 (Student’s t-test). GAG concentrations were 
normalized against urine creatinine contents. 
 
GAG accumulation was fully cleared in the visceral tissues of both of these 
treated groups (T1 and T18) (Figure 6). 
These data show that by using AAV2/5CMV-hIDS-mediated gene delivery, we 
were able to correct the metabolic disorder for up to 18 months of treatment. 
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Figure 6. Clearance of GAG Accumulation in all Tissues of Idsy/-+IDS (T1) and Idsy/-
+IDS (T18) Injected Mice 
Qualitative GAG accumulation measured by Alcian Blue staining of sections of all tissues of 
Idsy/- (T1-T14) and Idsy/-+IDS (T1-T18) mice. Magnification, 20x. 
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5. Characterization and complete correction of the brain defects in the 
treated MPSII mice 
The severe form of MPSII (MPSIIA) in human is characterized by mental 
retardation, cervical cord compression and foramen magnum stenosis, possibly 
leading to hydrocephalus 4. We analyzed the MPSII mice to check for the 
presence of neuropathological features within the CNS 32. 
The IDS activity that we measured in brain homogenates of MPSII mice was not 
detectable 32. Histopathological examination of brain sections were performed 
on MPSII mice at 4 months after birth by Toluidine-blue staining. Cellular 
vacuolization was detected in different regions of the brain in all of the Idsy/- 
mice examined: the hippocampus, thalamus, cerebellum and brainstem. In the 
cerebellum, reduced numbers and atypical morphology of the Purkinje cells 
were observed 32, probably due to the accumulation of GAGs, with consequent 
cell vacuolization and death. Finally, we evaluated GAG accumulation through 
Alcian-blue staining of the brain sections. GAG accumulation was detected 
within the choroid plexus of the ventricular region. 
Interestingly, we seen clearly diffuse neurodegeneration in the thalamus, 
cerebral cortex, and brainstem of untreated animals, through observation of 
reduced neuronal density (decreased anti-NeuN signal) and increased ubiquitin-
expressing neurons, as compared to the WT brain areas. This was also 
associated with the triggering of apoptosis, as shown by TUNEL positive signals 
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in neurons of the thalamus, cerebral cortex, and brainstem of MPSII mice 
(Figure 7A and Figures 8 and 9). In addition, in the white matter, there were α-
synuclein aggregates (Figure 4B), which have previously been shown to 
accumulate in neurons during neurodegenerative disorders, such as Parkinson 
disease and Alzheimer disease, and also during lysosomal storage disorders, 
such as Sandhoff disease, Tay-Sachs disease, metachromatic leukodystrophy, 
and β-galactosialidosis 53.  
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Figure 7. Rescue of Brain Defects in AAV2/5CMV-hIDS-Injected Idsy/- Mice 
(A and B) Immunohistochemistry of different brain-specific markers (monoclonal anti-NeuN, 
diluted 1:100; polyclonal anti-ubiquitin, diluted 1:50; TUNEL; monoclonal anti-GFAP, 
diluted 1:200; and monoclonal anti-CD68, diluted 1:250) in the thalamus and white matter 
(monoclonal anti-α-synuclein, diluted 1:250) of brain sections in T18 WT, T14 Idsy/-, and T18 
AAV2/5CMV-hIDS-injected Idsy/- mice. Magnification: 10x (anti-NeuN sections); 40x (anti-
CD68 sections); or 20x (all others). 
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Finally, in the untreated mice, there we found also increased numbers of 
activated microglia (GFAP immunohistochemistry) and massive infiltration of 
activated macrophages (CD68 positivity) (Figure 7A and Figures 8 and 9). 
 
Figure 8. Rescue of Brain Defects in Idsy/- Treated Mice 
Immunohistochemistry of different specific brain markers (anti-NeuN, anti-ubiquitin, 
TUNEL, anti-GFAP and anti-CD68) in cortex of wt (T18), Idsy/- (T14), Idsy/-+IDS (T18) 
brains. Magnification, 10x (anti-NeuN sections); 40x (anti-CD68 sections); 20x (all others). 
                                                                                                                                       
 54 
 
 
 
Figure 9. Rescue of Brain Defects in Idsy/- Treated Mice 
Immunohistochemistry of different specific brain markers (anti-NeuN, anti-ubiquitin, 
TUNEL, anti-GFAP and anti-CD68) in brain stem of wt (T18), Idsy/- (T14), Idsy/-+IDS (T18) 
brains. Magnification, 10x (anti-NeuN sections); 40x (anti-CD68 sections); 20x (all others). 
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In our previous work, the GAG accumulation was already partially rescued in 
the choroid plexus of IV ventricle in the treated adult MPSII mice, with AAV2/8 
serotype 32. This was surprising, given the presence of the hematoencephalic 
barrier. We predicted that because of the very high levels of IDS in the plasma, 
which ranged from 16- to 70-fold higher than the normal wild-type values, a 
fractional amount of the enzyme crosses the barrier and corrects the defect. To 
further confirm this result, we performed immunohistochemistry experiments. A 
group of MPSII mice were injected with 4.0 x 1012 AAV2/8TBG-IDS particles 
and sacrificed 1 month after the therapy. The brains and the livers of the injected 
mice and of non-injected and wild-type animals were included in OCT and the 
tissue sections were hybridized with an anti-hIDS polyclonal serum. This 
antibody recognizes only the human protein, and not the mouse form. The brain 
sections were also co-stained with an anti-Lamp2 monoclonal antibody, as a 
lysosomal marker. Positive lysosomal signals were detected in the brain and 
specifically in the cortex and cerebellum of the injected MPSII mice 32. A 
positive signal was also detected in the liver sections, as expected. No signal 
was present in the lysosomes of brains of wild-type or MPSII mice 32.  
To anticipate the disease manifestations and to obtain a therapeutic effect in the 
CNS, we systemically injected MPSII pups (p2) with 1.0 x 1011 AAV2/5CMV-
hIDS particles in the temporal vein. 
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The progressive accumulation of GAGs in lysosomes of neurons leads to severe 
GAG accumulation and vacuolization. This was cleared in neurons of the 
brainstem, cortex, hippocampus, and thalamus of treated mice. We confirmed 
the reduced cellular vacuolization by hematoxylin and eosin staining (Figure 
10).  
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Figure 10. Clearance of Vacuolization in Brain Sections of Treated Mice 
H&E stained sections of different regions of brains of wt (T18), Idsy/- (T14) and Idsy/-+IDS 
(T18) mice. Magnification, 20x (black box, 40x). 
 
GAG accumulation, by Alcian-blue staining, was fully cleared for both treated 
groups (T1, T18), remarkably, in all of the brain areas analyzed: the choroid 
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plexus in the IV and III ventricles, as well as the meninges, brainstem, cortex, 
hippocampus, and thalamus (Figure 11A and Figure 11B).  
Remarkably, in the T18 AAV2/5CMV-hIDS-injected Idsy/- mice, we found clear 
amelioration or complete correction of neurodegeneration (normalized staining 
of NeuN, ubiquitin, TUNEL, and α -synuclein), astrogliosis (normalized GFAP 
staining), and inflammation (normalized CD68 staining) (Figures 7A and 7B 
and Figures 8 and 9). Furthermore, in one-month-old MPSII mice, we observed 
increases in ubiquitin-expressing neurons and astroglysosis in the thalamus, 
including an increase in α -synuclein aggregates as well; these markers were 
normalized in the group of T1 AAV2/5CMV-hIDS-injected Idsy/- mice (Figures 
12A and 12B).  
All of these data demonstrate that with this therapy, it’s possible to prevent the 
development of the CNS defects, along with the somatic manifestations.  
These data clearly showed that, even if only a partial rescue of the IDS activity 
in the brain was succeeded with this therapy, this constant low level of IDS that 
had crossed the BBB was sufficient to totally clear the GAG CNS storage. 
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Figure 11. Clearance of GAG Accumulation in Idsy/-+IDS (T1) and Idsy/-+IDS (T18) Mice 
 (A-B) Alcian Blue-stained sections for GAG accumulation in different regions of brains of 
Idsy/- (T1), T14 Idsy/- control mice, Idsy/-+IDS (T1), and T18 AAV2/5CMV-hIDS-injected 
Idsy/- mice. Magnification: 20x. 
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Figure 12. Rescue of Brain Defects in Idsy/- Treated T1 Mice 
(A) Immunohistochemistry of specific brain markers (anti-ubiquitin, anti-GFAP) in thalamus 
of wt (T1), Idsy/- (T1) and Idsy/-+IDS (T1) brain sections. (B) Immunohistochemistry of anti-
α-synuclein in white matter of the same groups of mice. Magnification, 20x. 
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6. Crossing of Blood-Brain Barrier (BBB) by IDS enzyme 
To determine whether the observed GAG clearance and increased IDS activity 
in the brain of treated MPSII mice were due to the cross of the enzyme through 
the blood-brain barrier, and not to the transduction of the brain by the viral 
particles, we analyzed the β -galactosidase activities of the group of wild-type 
mice (n = 2) that were injected with AAV2/5CMV-LacZ.  
Human IDS expression in cDNAs from T1 and T18 tissues was analyzed. No 
positive expression signals were detected in the brain samples of the control 
(WT and Idsy/-) or treated (T1 and T18) mice. In contrast, we found clear 
amplification of IDS expression in the liver and lungs of both treated groups. 
For controls, we also amplified mouse Ids transcripts (Figure 13A and Figure 
14). For further confirmation of these results, p2 WT mice were injected with 
1.0 x 1011 AAV2/5CMV-LacZ viral particles. LacZ expression and β -
galactosidase activity were seen only in the liver and lungs, not in the brain 
(Figure 13B). This indicates that both of the hIDS and LacZ transgenes from the 
AAV2/5 vectors were not expressed in the brains of the injected mice and that, 
thus, the measured IDS activity was due to IDS uptake from the bloodstream 
and its crossing of the BBB. Similarly, by using real-time PCR, we could not 
detect any AAV2/5 viral genomic DNA in the brains of the treated mice, only in 
their livers, further ruling out crossing of the BBB by AAV2/5 and transduction 
of the brains (Figure 13C).  
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Figure 13. IDS Protein Crossing of the BBB in AAV2/5CMV-hIDS -Injected Idsy/- Mice 
(A) RT-PCR of IDS from brains, livers, and lungs of T18 WT, T14 Idsy/-, and T18 Idsy/- +IDS 
mice, for amplification of human and mouse IDS mRNA. 
(B) WT mice injected at p2 in the temporal vein with AAV2/5CMV-LacZ and sacrificed after 
1 month. RT-PCR of LacZ mRNA from brains, livers, and lungs of T1 WT and T1 WT+LacZ 
mice. (C) Real-time PCR for amplification of viral genomic DNA in brains and livers of T1 
nontreated Idsy/- mice (n = 4) and T1 AAV2/5CMVhIDS-injected Idsy/- mice (n = 4). Error 
bars indicate standard deviations. p < 0.05 (Student’s t test).  
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Figure 14. IDS Protein Crossing of the BBB in Idsy/-+IDS (T1) Injected Mice 
(A-C) RT-PCR of hIDS and mIDS mRNAs from brains, livers and lungs of wt (T1), Idsy/- 
(T1), Idsy/-+IDS (T1) mice. 
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By contrast, efficient crossing of the BBB was achieved by intravenous 
injections of the AAV9 vector 54.  
In other words, this result confirms that even if the CMV promoter allows 
expression of the viral particles in some tissues (such as liver and lung), the IDS 
activity that was measured in the brain is due to the uptake of the enzyme from 
the blood-brain barrier. 
 
7. Corrections of the locomotor defects in the treated MPSII mice and their 
performance at the open-field test  
The MPSII mice showed drastic skeleton deformation at 4 months of age, which 
included craniofacial abnormalities, macrodactyly, thickening of the digits and 
clear craniofacial abnormalities, seen as a short cranium 32. 
The treated T18 AAV2/5CMV-hIDS-injected Idsy/-, untreated and wild-type 
mice of the same age underwent the open-field test throughout the therapy 
period to determine horizontal and vertical activities and confirming their 
improved gross motor phenotype. Figures 15A and 15B show the results of the 
tests performed at T18. The ability to explore, the locomotion and the anxiety to 
move of the treated, untreated and wild-type mice were determined. 
The mice underwent three trials for 5 min at the end of the therapy (T18). We 
measured the total distance traveled by the animals during the trial (the number 
of squares crossed or horizontal activity) and the rearing activity (vertical 
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activity). The treated MPSII mice behaved as the wild-type ones: they were 
more active, faster and had no anxiety to explore the space around them; their 
rearing frequencies, where the mice stood on their hind legs, were also 
comparable. In contrast, the untreated MPSII mice were much slower and more 
anxious to explore, and their rearing was poor. Furthermore, the untreated 
MPSII mice spent a lot of time in the margin area of the field and crossed the 
center of the open-field apparatus only rarely; in contrast, the treated MPSII 
mice and the wild-type mice moved fast from the center to the margin area and 
without hesitation (Figure 15A and figure 15B).  
In conclusion, the AAV2/5 IDS gene delivery completely restored the locomotor 
defects of the MPSII mice. 
All in all, these data clearly demonstrates that with only one intravenous 
systemic injection of AAV2/5CMV-hIDS vector particles administered to 
newborn p2 Idsy/- mice, the mice do not develop the systemic and CNS disease 
phenotypes up to 18 months of age. We clearly shown that the vector was not 
transduced in the brains of the treated animals and that the correction of the CNS 
symptoms was due to the crossing of the BBB by IDS. 
 
                                                                                                                                       
 66 
 
Figure 15. Idsy/- Treated Mice Underwent the Open-Field Test 
(A, B) Horizontal and vertical activities measured in Idsy/-+IDS (T18, n = 4) and control Idsy/- 
(T14, n = 3) mice. The error bars indicate standard deviations. P <0.05 (Student’s t-test). 
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DISCUSSION 
LSDs, such as Gaucher disease, metachromatic leukodystrophy and MPS, 
include more than 40 disorders that are caused by defective activities of 
lysosomal enzymes and that result in the accumulation of undegraded 
metabolites within the lysosomes. 
Most LSDs exist in severe infantile forms that present brain involvement, where 
the patients die within the first few years of life. There are also adult forms of 
LSDs that are characterized by the slow development of the peripheral 
symptoms, which results in physical disabilities. Finally, there are the juvenile 
forms of intermediate to severe manifestations of LSDs 55. Although each LSD 
has a particular clinical and pathological picture, the pathological features can be 
summarized as neurological symptoms, including seizures, dementia and 
brainstem dysfunction, and peripheral symptoms, including 
hepatosplenomegaly, heart and kidney injury, skeleton malformations, muscle 
atrophy, ocular disease and hearing impairment. 
The accumulation of undegraded metabolites within the lysosomes is the 
primary cause of the disease. However, it has been suggested that the various 
ranges of clinical symptoms also activate secondary pathways, such as cellular 
dysfunction, because of the altered activation of biochemical pathways and 
altered gene expression. Overall, these altered primary and secondary pathways 
cause tissue pathology and general organ damage 56; 57. 
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The therapies currently at the stage of preclinical or clinical trials for many of 
the LSDs are ERT, cellular therapies, such as BMT, and virus-mediated gene 
therapy. 
The choice between these three therapeutic approaches relates to their different 
efficacies with respect to the different LSDs. In particular, for the treatment of 
MPSII, or Hunter syndrome, which is characterized by the inactivity of the IDS 
enzyme and the consequent accumulation of heparan and dermatan sulfates 
(GAGs) within the lysosomes, at present, ERT and BMT result in doubtful 
prognoses for prolonged positive outcomes 58-61. Attempts of therapy for MPSII 
are palliative and focused on management of the clinical symptoms. This is also 
due to the limited number of patients under treatment and to their short length of 
follow-up. Moreover, in the ERT, the patients receive weekly expensive 
injection of IDS enzyme; these repeated administrations at long run could cause 
an immuno-response against IDS protein, reversing the therapeutic effect. 
Additionally, the ERT protocol is able to partially rescue the visceral phenotype 
of MPSII patients, but not the CNS one. 
Thus, as a mouse model for MPSII is available, we have designed an efficient 
gene-therapy protocol. 
We have investigated the MPSII mouse model for its gross phenotypic 
characteristics and metabolic defects. Furthermore, we analyzed 
neuropathological features within the CNS. 
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Then, we systemically delivered the IDS gene into the temporal vein using 
AAV2/5 vectors. We have been able to specifically transduce some tissues (such 
as the liver and the lung) and to promote the production of human IDS in these 
tissues. The enzyme was then secreted efficiently into the blood stream, and it 
targeted all of the nontransduced tissues with great efficiency. Complete 
correction of the visceral, CNS and locomotor defects was achieved. 
A partial rescue of the IDS activity in the CNS was also observed. The AAV 
vectors 62 transduce murine tissues efficiently and their production allows the 
exchange of the surface proteins (the capsid) between different serotypes 51; 52; 63-
65. The hybrid vectors contain the genome packaged in capsids from different 
AAV serotypes and detain effective transduction characteristics, resulting in 
excellent efficacy of gene expression and tissue tropism. In fact, AAV2/1 and 
2/7 vectors transduce muscle very powerfully 41; 64; 65, AAV2/5 tranduces lung 
by entering the airway from the apical side and other tissues 51; 52; 66 and AAV2/8 
is the most efficient AAV vector for liver-directed gene transfer 41. 
We used the CMV promoter to express the IDS gene; this is a ubiquitous 
promoter. Thus, the combination of AAV5 and the CMV promoter was 
extremely useful for the production of high levels of the circulating IDS enzyme 
and could represent a valuable tool for the treatment of MPSII patients.  
Usually, the correction of MPS defects can be achieved by restoring the 
enzymatic activities to up to only 1–10% of their normal levels 67; in the present 
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study, we have restored the IDS activity with respect to the normal wild-type 
levels. We injected the viral particles at 1.0 x 1011 per kilogram in our 
experiments and we were able to obtain high levels of IDS in the plasma, which 
ranged 5 times higher than the normal wild-type values.  
For the future, this is a valuable concept, as it should scale down the amounts of 
viral particles that might be needed in the treatment of larger animals and of 
humans in clinical trials. 
In this study, the high levels of the circulating IDS enzyme have resulted in its 
crossing of the hemato-encephalic barrier, leading to a partial rescue of the IDS 
deficiency, along with the complete clearance of the GAGs in different regions 
of brain and complete rescue of neurodegenerative defects. 
In this thesis, the crossing of BBB has represented a crucial and necessary point. 
In fact, the major limit in the treatment and cure of most neurodegenerative 
diseases, is just the cross of BBB that surround and protect the brain 68. 
Although at present it is still unknown how IDS crosses the BBB, the long half-
life of circulating IDS, as shown by its slow clearance from the blood (high 
plasma levels in treated animals), probably allows the enzyme to cross the BBB. 
Interestingly, chemically modified β -glucuronidase showed slower plasma 
clearance, and the modified enzyme efficiently crossed the BBB after its 
systemic infusion in MPSVII mice 69. 
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Partial correction of CNS defects has been described in a mouse model of 
MPSVII after intrahepatic administration of AAV2 vectors 50. Furthermore, a 
therapeutic effect in the brain has also been shown by administration of high 
doses of enzyme through ERT. Both β-glucuronidase and α -mannosidase were 
able to cross the hemato-encephalic barrier in MPSVII and in α -mannosidosis 
mouse models, respectively 47; 48.  
Whether high circulating levels of IDS are required for its delivery through 
receptor-mediated uptake or via different routes, such as pinocytosis or 
transcytosis, remains an open question. MPSII patients affected by the severe 
form of the disease ideally need to be treated with one administration of the 
vector that can rescue both visceral and CNS defects.  
Nevertheless, these findings have demonstrated that high circulating levels of 
the IDS enzyme, coupled with very early treatment of the mice, provide an 
effective therapy for MPSII in all of the affected tissues. Potentially, modulation 
of the physical parameters of the enzymes, such as their stability, and early 
vector administration might be useful approaches for the treatment of other 
lysosomal-storage disorders. 
In conclusion, the systemic delivery of IDS through AAV2/5 vectors is highly 
efficient and represents a promising approach for future applications in the 
therapy of MPSII patients. 
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Furthermore, it can be considered as proof of principle for the treatment of LSDs 
including other sulfatase deficits, in particular for those diseases that involve the 
CNS. The systemic distribution of the active enzyme might represent an 
efficient way of delivery for many of the metabolic disorders affecting different 
tissues and brain. 
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